- Report
- February 2024
- 90 Pages
Asia Pacific
From €4175EUR$4,750USD£3,611GBP
- Report
- February 2024
- 80 Pages
Latin America
From €4175EUR$4,750USD£3,611GBP
- Report
- February 2024
- 80 Pages
Europe
From €4175EUR$4,750USD£3,611GBP
- Report
- February 2024
- 70 Pages
Indonesia
From €4175EUR$4,750USD£3,611GBP
- Report
- February 2024
- 70 Pages
Philippines
From €4175EUR$4,750USD£3,611GBP
- Report
- February 2024
- 70 Pages
India
From €4175EUR$4,750USD£3,611GBP
- Report
- August 2023
- 70 Pages
Africa, Middle East
From €4175EUR$4,750USD£3,611GBP
- Report
- August 2023
- 70 Pages
South Korea
From €4175EUR$4,750USD£3,611GBP
- Report
- October 2022
- 70 Pages
Africa
From €4175EUR$4,750USD£3,611GBP
- Report
- February 2024
- 150 Pages
Global
From €4175EUR$4,750USD£3,611GBP
- Report
- August 2023
- 90 Pages
Global
From €4175EUR$4,750USD£3,611GBP
- Report
- August 2023
- 150 Pages
North America
From €4175EUR$4,750USD£3,611GBP

Janumet is a medication used to treat type 2 diabetes, a condition in which the body does not produce enough insulin or does not use insulin properly. It is a combination of two drugs, sitagliptin and metformin, which work together to lower blood sugar levels. Janumet is part of the Endocrine and Metabolic Disorders Drugs market, which includes medications used to treat a variety of conditions, such as diabetes, thyroid disorders, and obesity. These drugs are used to help regulate hormones and metabolism, and can help improve quality of life for those with these conditions.
Some companies in the Janumet market include Merck & Co., Inc., AstraZeneca, and Boehringer Ingelheim. Show Less Read more